Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957
Gabather AB (Nasdaq First North Growth Market: GABA), a clinical stage pharmaceutical company developing novel therapeutics for neuropsychiatric disorders, is pleased to announce that it has received approval from the JPO for the national phase patent application No. 2020-554957.
The invention relates to the synthesis and production of triazoloquinazolinones and is based on the PCT International Application No. PCT/IB2018/001573. The invention expands our position in the field of GABAA receptor modulators and medical use. This patent together with our patent portfolio covers key products and methods that creates substantial value to the company and shareholders, giving Gabather both the freedom to operate and important differentiation of our products.
“We are pleased that the JPO has approved and issued the certificate of patent in Japan. It further strengthens our drug products and competitive advantage in providing novel neuropsychiatric drugs to the patients”, says Dr. Michael-Robin Witt, CEO of Gabather.
For further information, please contact:
Dr. Michael-Robin Witt, CEO
Phone: 073-687 28 39
E-mail: [email protected]
Briefly about Gabather AB
Based on pioneering research at Lund University and the Research Institute for Biological Psychiatry in Roskilde, Gabather was founded in 2014 with the aim of developing innovative and effective therapies for neuropsychiatric disorders. Our research and development focus on developing new pro-cognitive drug candidates targeting the GABAA receptor for the treatment of disorders and imbalances in the central nervous system (CNS). GABAA receptors are the main inhibitory signalling system in the brain that regulates central CNS functions. Dysfunction or imbalance in this system is known to be at the core of many neurological and neuropsychiatric disorders. The Company Certified Adviser is Erik Penser Bank, Phone. 08- 463 80 00, [email protected]
